HUGE - Rasio utang marang kapitalisasi buku fsdpharma.com

The current debt-to-equity ratio on the GURU.Markets chart illustrates borrowing dynamics, where the 0.05 level captures the latest values. FSD Pharma Inc. is developing a diversified portfolio of drugs for the therapy of nervous system disorders. However, the lack of approved medications and a liquidity deficit create serious operational risks. The company is currently cutting costs and divesting assets, having completely abandoned external acquisitions.

For FSD Pharma Inc. (HUGE), which develops innovative drugs for neurological disorders, this indicator compares total liabilities to equity. The metric determines the extent to which the development of biotechnological research depends on borrowed funds. By analyzing the debt-to-capitalization ratio on the balance sheet, an investor assesses the risk of insolvency. Low values confirm the company's autonomy, ensuring business stability during the implementation of long-term scientific strategies.